OMER

Rating neutralAI Memo

Omeros

As of 2026-09-10/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

YARTEMLEA CMS NTAP reimbursement • 2026-10-01

Base target: $21 / p=50% prob

Biggest risk

The company remains dependent on execution for a recently launched product, with limited disclosed analyst coverage. The EMA negative opinion creates regulatory and geographic downside, while pipeline milestones remain early and uncertain.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

YARTEMLEA's first full commercial quarter showed strong revenue growth and positive operating cash flow, while debt repurchases reduced future interest expense and potential dilution. CMS reimbursement support could improve access and sustain the launch.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-10

Base target

$21

p=50%

Bull target

$28

p=25%

Bear target

$12

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

YARTEMLEA commercial ramp and cash conversion
Pipeline and indication-expansion milestones
YARTEMLEA's first full commercial quarter showed strong revenue growth and positive operating cash flow, while debt repurchases reduced future interest expense and potential dilution.

BearKey bullets

Capital structure remains a risk despite note repurchases, and the company may require additional financing if commercial cash generation disappoints.
EMA re-examination may fail or be delayed after the negative CHMP opinion.
Recent officer and director open-market sales are a sentiment headwind but are not evidence of operating performance.

WatchKey bullets

YARTEMLEA CMS NTAP reimbursement

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $21 (p=50%)

Target spread vs base: +33% / -43%

Scenario probabilities

Bull Target: $28 (p=25%)Base Target: $21 (p=50%)Bear Target: $12 (p=25%)

Commentary

Headline tone is constructive after Q2 YARTEMLEA sales, CMS support, and capital-structure actions, but the EMA setback offsets part of the upside. The packet includes a secondary headline reporting a sharp after-hours gain, but trusted post-release price follow-through is unavailable. Analyst revisions, target changes, options data, short interest, and employee sentiment are unavailable; this remains a low-coverage monitoring setup rather than a high-conviction bullish call.

As of 2026-09-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

YARTEMLEA commercial ramp and cash conversion
Pipeline and indication-expansion milestones

Scenarios

Bull Target (Scenario probability)

$28 / p=25% prob

Base Target (Scenario probability)

$21 / p=50% prob

Bear Target (Scenario probability)

$12 / p=25% prob

Analysis 2026-09-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.45

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-01
YARTEMLEA CMS NTAP reimbursement
CMS granted YARTEMLEA New Technology Add-on Payment status effective October 1, 2026, supporting eligible hospital reimbursement and patient access. [#SEC-8K-2026-08-12]
Prob 90.00% • Move 8.00% • Priced-in 60.00%
EVENT2026-12-09
EMA narsoplimab re-examination
The EMA adopted a negative opinion on narsoplimab in TA-TMA, and Omeros requested re-examination with external expert review. A favorable outcome could expand European opportunity, while delay or rejection remains a material downside risk. [#SEC-8K-2026-08-12]
Prob 35.00% • Move 25.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

YARTEMLEA commercial ramp and cash conversion
2026-12-09
Q2 gross YARTEMLEA revenue reached $32.2 million, up 190% quarter over quarter; net revenue was $28.5 million and operating cash flow was $4.1 million. Adjusted net income was $1.8 million, while GAAP income benefited from non-cash derivative gains. The results were reported in Omeros's investor release furnished with [#SEC-8K-2026-08-12].
Prob 70% • Move 12% • Priced-in 70%

Long-term Catalysts

Months to a year

Pipeline and indication-expansion milestones
2027-09-10
Management expects enrollment by year-end 2026 in two YARTEMLEA studies, including hyperinflammatory ARDS and pediatric TA-TMA, and continues work toward Phase 3 initiation for zaltenibart with Novo Nordisk. These are execution-dependent and not yet valuation-grade catalysts. [#SEC-8K-2026-08-12]
Prob 55% • Move 15% • Priced-in 35%

Risks

Capital structure remains a risk despite note repurchases, and the company may require additional financing if commercial cash generation disappoints.
EMA re-examination may fail or be delayed after the negative CHMP opinion.
Recent officer and director open-market sales are a sentiment headwind but are not evidence of operating performance. [#SEC-FORM4-2026-09-01]
Reported GAAP earnings were materially affected by non-cash derivative gains; adjusted profitability and cash generation remain more decision-relevant.
Revenue concentration in YARTEMLEA increases exposure to one commercial product and execution path.
YARTEMLEA demand, reimbursement uptake, gross-to-net dynamics, or hospital adoption may not sustain the initial launch trajectory.

Peers

Symbol	Summary
CRVS	Closest size-matched same-sector reference in the packet, but its operating model and commercial comparability to OMER are limited.
IMTX	Similar market-cap biotechnology reference; valuation is milestone-driven and not directly comparable to Omeros's commercial YARTEMLEA profile.
GILD	Large-cap biopharma commercialization benchmark rather than a direct valuation peer; useful mainly for scale and diversification context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-10

Loading AI feed…

Symbol

Summary

CRVS

Closest size-matched same-sector reference in the packet, but its operating model and commercial comparability to OMER are limited.

IMTX

Similar market-cap biotechnology reference; valuation is milestone-driven and not directly comparable to Omeros's commercial YARTEMLEA profile.

GILD

Large-cap biopharma commercialization benchmark rather than a direct valuation peer; useful mainly for scale and diversification context.